Haemate HS in Patients With Severe Bleeding Undergoing Valve Replacement Due to Aortic Stenosis
Status:
Withdrawn
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Evaluation of efficacy by determination of transfusion requirements and safety by
determination of adverse events in administration of Von Willebrand factor concentrate F VIII
(Haemate).